Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-03-17
2008-11-18
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S093400
Reexamination Certificate
active
07452531
ABSTRACT:
The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
REFERENCES:
patent: 4436727 (1984-03-01), Ribi
patent: 5021234 (1991-06-01), Ehrenfeld
patent: 5318900 (1994-06-01), Habuka et al.
patent: 5344762 (1994-09-01), Karapetian
patent: 5705151 (1998-01-01), Dow et al.
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5830702 (1998-11-01), Portnoy et al.
patent: 5877159 (1999-03-01), Powell et al.
patent: 5997881 (1999-12-01), Powell et al.
patent: 6051237 (2000-04-01), Paterson
patent: 6080849 (2000-06-01), Bermudes et al.
patent: 6143551 (2000-11-01), Goebel et al.
patent: 6150170 (2000-11-01), Powell et al.
patent: 6190657 (2001-02-01), Pawelek et al.
patent: 6251406 (2001-06-01), Haefliger et al.
patent: 6410012 (2002-06-01), Sizemore et al.
patent: 6447784 (2002-09-01), Bermudes et al.
patent: 6475482 (2002-11-01), Bermudes et al.
patent: 6537558 (2003-03-01), Kaniga
patent: 6605286 (2003-08-01), Steidler et al.
patent: 6685935 (2004-02-01), Pawelek et al.
patent: 6863894 (2005-03-01), Bermudes et al.
patent: 6923972 (2005-08-01), Bermudes et al.
patent: 6962696 (2005-11-01), Bermudes et al.
patent: 7354592 (2008-04-01), Bermudes et al.
patent: 2001/0006642 (2001-07-01), Steidler et al.
patent: 2001/0029043 (2001-10-01), Haefliger, et al.
patent: 2003/0059400 (2003-03-01), Szalay et al.
patent: 2004/0229338 (2004-11-01), King et al.
patent: 2007/0298012 (2007-12-01), King et al.
patent: 719446 (2000-08-01), None
patent: 749695 (2002-07-01), None
patent: 783714 (2006-03-01), None
patent: PI-9609016-2 (1996-06-01), None
patent: PI-9812079-4 (2000-03-01), None
patent: PI-0014491-6 (2002-04-01), None
patent: 2224075 (1997-12-01), None
patent: 2302866 (2000-03-01), None
patent: 2386465 (2002-04-01), None
patent: 00816714.1 (2000-06-01), None
patent: ZL96196140.6 (2004-02-01), None
patent: ZI98811030.X (2006-04-01), None
patent: 0285152 (1986-03-01), None
patent: 00195672 (1986-09-01), None
patent: 0322237 (1989-06-01), None
patent: 0338679 (1989-10-01), None
patent: 89302712.6. (1989-10-01), None
patent: 0357208 (1990-03-01), None
patent: 0400958 (1990-12-01), None
patent: 0564121 (1993-10-01), None
patent: 98 94 6891 (1998-09-01), None
patent: 1012232 (2000-06-01), None
patent: 1261369 (2002-12-01), None
patent: 0833660 (2006-12-01), None
patent: 03108220.2 (2003-11-01), None
patent: 1017253 (2004-07-01), None
patent: 1033956 (2006-11-01), None
patent: 134936 (2000-07-01), None
patent: 148933 (2002-03-01), None
patent: 122407 (2007-12-01), None
patent: 62-145026 (1987-06-01), None
patent: 63-101328 (1988-06-01), None
patent: 01-180630 (1989-07-01), None
patent: 06046890 (1994-02-01), None
patent: 62-298657 (1994-10-01), None
patent: 2000-510842 (2000-03-01), None
patent: 2001-528552 (2002-04-01), None
patent: 2004-500042 (2002-04-01), None
patent: 3482213 (2003-10-01), None
patent: 7002535/2000 (2000-03-01), None
patent: 7004371/2002 (2002-04-01), None
patent: 0435932 (2004-06-01), None
patent: 979439 (1997-12-01), None
patent: 2000002355 (2000-03-01), None
patent: 2002003384 (2002-04-01), None
patent: A/2008/001378 (2008-01-01), None
patent: 312341 (1999-09-01), None
patent: 518354 (2002-02-01), None
patent: 503376 (2002-10-01), None
patent: 51176 (1998-12-01), None
patent: 200201817-4 (2002-04-01), None
patent: 71486 (2004-04-01), None
patent: WO 91/06317 (1991-05-01), None
patent: WO 92/11361 (1992-07-01), None
patent: WO/92/15689 (1992-09-01), None
patent: WO 95/02048 (1995-01-01), None
patent: WO/95/05835 (1995-03-01), None
patent: WO/95/09655 (1995-04-01), None
patent: WO 96/11277 (1996-04-01), None
patent: WO 96/34631 (1996-11-01), None
patent: WO 96/40238 (1996-12-01), None
patent: WO 97/08955 (1997-03-01), None
patent: WO 97/18225 (1997-05-01), None
patent: WO 97/18837 (1997-05-01), None
patent: WO 97/19688 (1997-06-01), None
patent: WO 97/25061 (1997-07-01), None
patent: WO 98/33923 (1998-08-01), None
patent: WO 89/53854 (1998-12-01), None
patent: WO 99/13003 (1999-03-01), None
patent: WO/99/13053 (1999-03-01), None
patent: WO 99/52563 (1999-10-01), None
patent: WO 00/09733 (2000-02-01), None
patent: WO/01/25397 (2001-04-01), None
patent: WO 02/20809 (2002-03-01), None
patent: 98/8289 (1999-05-01), None
Dietrich et al (Antisense & Nucleic Acid Drug Development 10:391-399, 2000.
Curtiss R. J. Clin. Invest. 110(8):1061-1066, 2002.
Titball et al Vaccine 19:4175-4184, 20001.
Grillot-Courvalin (Nature Biotechnology, 1998, 16: 862-866.
Dietrich et al (Nature Biotechnology, 1998, 16: 181-185).
Pascual et al (Behring Inst. Mitt., 1997, 98: 143-152).
Boehm et al. Nature 390:404-407, (1997).
Iruela-Arispe et al, Circulation 1999;100:1423-31.
Gupta et al, PNAS 1995;92:7799-7803.
Adler, 1973, “A Method for Measuring Chemotaxis and Use of the Method to Determine Optimum Conditions for Chemotaxis byEscherichia coli,” 3. Gen. Microbiol. 74:77-91.
Alizadeh, et al., 1994, “Apoptosis as a Mechanism of Cytolysis of Tumor Cells by a Pathogenic Free-Living Amoeba,” Infect. Immun. 62:1298-1303.
Anderson, et al., 1996, “Development of attenuatedSalmonellastrains that express heterologous antigens,” Methods in Molecular Medicine: Vaccine protocols, ed. Robinson A., Farrar G., Wiblin C., Humana Press, New Jersey, pp. 47-62.
Anderson WF, 2001, “Recombinant DNA Advisory Committee Meeting on Issues of Concern to IBCs,” Human Gene Therapy 12(12): 1594-1596.
Bagshawe, 1995, “Antibody-Directed Enzyme Prodrug Therapy: A Review,” Drug Dev. Res. 34:220-230.
Barry, et al., 1995, “Protection Against Mycoplasma Infection Using Expression-Library Immunization,” Nature 377:632-635.
Barth and Morton, 1995, “The Role of Adjuvant Therapy in Melanoma Management,” Cancer 75 (Suppl.):726-734.
Berggren, 1995, “RecombinantSalmonellaas an Oral HIV Vaccine,” NIH Project No. 5 K08 AI01248-02.
Bermudes, et al., 2000, “Tumor targetedSalmonella. Strain development and expression of the HSV TK effector gene,” Gene Therapy, Methods and Protocols, vol. 35, 419-436.
Bermudes, et al., 2000, “Tumor-targetedSalmonella. Highly selective delivery vectors,” Advances in Exp. Med. And Bio. 465:57-63.
Boehm, et al., 1997, “Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance,” Nature 390(6658):404-407.
Bone, 1993, “Gram-Negative Sepsis: A Dilemma of Modern Medicine,” Clin. Microbiol. Rev. 6:57-68.
Bonnekoh, et al., 1995, “Inhibition of Melanoma Growth by Adenoviral-Mediated HSV Thymidine Kinase Gene Transfer in vivo,” J. Invest. Derm. 104:313-317.
Carey, et al., “Clostridial Oncolysis in Man,” Eur. J. Cancer 3:37-46.
Carrier, et al., 1992, “Expression of Human IL-1B inSalmonella typhimurium; a Model System for the Delivery of Recombinant Therapeutic Proteins in vivo,” J. Immunol. 148:1176-1181.
Carswell, et al., 1975, “An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors,” Proc. Natl. Acad. Sci. USA 72:3666-3670.
Chabalgoity, et al., 1996, “ASalmonella typhimuriumhtrA Live Vaccine Expressing Multiple Copies of a Peptide Comprising Amino Acids 8-23 of Herpes Simplex Virus Glycoprotein D as a Genetic Fusion to Tetanus Toxin Fragment C Protects Mice from Herpes S
Belcourt Michael
Bermudes David G.
Clairmont Caroline A.
King Ivan C.
Law Offices of Albert Wai-Kit Chan PLLC
Li Q. Janice
Vion Pharmaceuticals Inc.
LandOfFree
Compositions and methods for tumor-targeted delivery of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for tumor-targeted delivery of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for tumor-targeted delivery of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4046598